174 related articles for article (PubMed ID: 24065800)
1. Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Oct; 62(10):e19-22. PubMed ID: 24065800
[No Abstract] [Full Text] [Related]
2. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Engel SS; Golm GT; Lauring B
Diabetes; 2013 Oct; 62(10):e18. PubMed ID: 24065799
[No Abstract] [Full Text] [Related]
3. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Heine RJ; Fu H; Kendall DM; Moller DE
Diabetes; 2013 Oct; 62(10):e16-7. PubMed ID: 24065798
[No Abstract] [Full Text] [Related]
4. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
[TBL] [Abstract][Full Text] [Related]
5. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
Bonner-Weir S; In't Veld PA; Weir GC
Diabetes Obes Metab; 2014 Jul; 16(7):661-6. PubMed ID: 24400596
[TBL] [Abstract][Full Text] [Related]
6. Incretin therapy and islet pathology: a time for caution.
Kahn SE
Diabetes; 2013 Jul; 62(7):2178-80. PubMed ID: 23596147
[No Abstract] [Full Text] [Related]
7. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Ueberberg S; Jütte H; Uhl W; Schmidt W; Nauck M; Montanya E; Tannapfel A; Meier J
Diabetes Obes Metab; 2016 Dec; 18(12):1253-1262. PubMed ID: 27545110
[TBL] [Abstract][Full Text] [Related]
8. Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
Cox AR; Lam CJ; Rankin MM; Rios JS; Chavez J; Bonnyman CW; King KB; Wells RA; Anthony D; Tu JX; Kim JJ; Li C; Kushner JA
Endocrinology; 2017 Jun; 158(6):1701-1714. PubMed ID: 28323942
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
10. Lipotoxicity impairs incretin signalling.
Poitout V
Diabetologia; 2013 Feb; 56(2):231-3. PubMed ID: 23188391
[TBL] [Abstract][Full Text] [Related]
11. Novo Nordisk incretin leadership summit, Cape Town.
Cardiovasc J Afr; 2012 Jun; 23(5):288-92. PubMed ID: 23077732
[No Abstract] [Full Text] [Related]
12. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
13. Choosing among the incretin agents and why it matters.
Unger J
J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
[No Abstract] [Full Text] [Related]
14. The role of incretin on diabetes mellitus.
Sanusi H
Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.
Martin JH; Deacon CF; Gorrell MD; Prins JB
Intern Med J; 2011 Apr; 41(4):299-307. PubMed ID: 21299778
[TBL] [Abstract][Full Text] [Related]
16. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.
Salehi M; Aulinger BA; D'Alessio DA
Endocr Rev; 2008 May; 29(3):367-79. PubMed ID: 18292465
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
Kang ZF; Deng Y; Zhou Y; Fan RR; Chan JC; Laybutt DR; Luzuriaga J; Xu G
Diabetologia; 2013 Feb; 56(2):423-33. PubMed ID: 23188390
[TBL] [Abstract][Full Text] [Related]
20. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
Moses A
BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
